Skip to main content
. 2023 May 23;12(6):e220188. doi: 10.57264/cer-2022-0188

Table 1. . Data inputs for the network meta-analysis.

HAE attack rate per 28 days† Study Arm 1 Arm 2 Rate in arm 1 Rate in arm 2 Rate ratio Ref.
  HELP Lanadelumab 300 mg Q2W Placebo 0.26 1.97 0.13 [13]
  HELP Lanadelumab 300 mg Q4W Placebo 0.53 1.97 0.27 [13]
  HELP Lanadelumab 300 mg Q2W Lanadelumab 300 mg Q4W 0.26 0.53 0.49 [13]
  APeX-2 Berotralstat 110 mg q.d. Placebo 1.65 2.35 0.70 [17]
  APeX-2 Berotralstat 150 mg q.d. Placebo 1.31 2.35 0.56 [17]
  APeX-2 Berotralstat 110 mg q.d. Berotralstat 150 mg q.d. 1.65 1.31 1.26 [17]
  CHANGE C1-INH 1000 IU BIW Placebo 2.10 4.23 0.50 [20]
Probability of achieving ≥90% reduction in the monthly HAE attack rate ‡ Study Arm 1 Arm 2 Proportion in arm 1 Proportion in arm 2 ARR §  
  HELP Lanadelumab 300 mg Q2W Placebo 0.67 0.05 –0.62 [13]
  HELP Lanadelumab 300 mg Q4W Placebo 0.55 0.05 –0.50 [13]
  HELP Lanadelumab 300 mg Q2W Lanadelumab 300 mg Q4W 0.67 0.55 –0.12 [13]
  APeX-2 Berotralstat 110 mg q.d. Placebo 0.10 0.08 –0.02 [17]
  APeX-2 Berotralstat 150 mg q.d. Placebo 0.23 0.08 –0.15 [17]
  APeX-2 Berotralstat 110 mg q.d. Berotralstat 150 mg q.d. 0.10 0.23 0.13 [17]
  CHANGE C1-INH 1000 IU BIW Placebo 0.18 0 –0.18 [34]
Risk in comparator group Placebo C1-INH 1000 IU BIW Berotralstat 150 mg q.d. Berotralstat 110 mg q.d. Lanadelumab 300 mg Q2W Lanadelumab 300 mg Q4W  
HAE attack rate per 28 days – base case analysis 2.41 4.23 2.35 2.35 1.97 1.97  
HAE attack rate per 28 days – steady-state sensitivity analysis 2.51 4.23 2.35 2.35 1.88 1.88  
≥90% reduction in the monthly HAE attack rate 0.08 0.18 0.08 0.08 0.05 0.05  
†

HAE attack rate per 28 days takes into account the whole observed time horizon (number of events per patient-days at risk).

‡

Probabilities of achieving ≥90% reduction in the number of monthly HAE attacks are estimated as relative reductions in HAE attack rates on treatment compared with prospectively collected HAE attack rates at baseline.

§

ARR is estimated as proportion in arm 1 subtracted from proportion in arm 2.

For C1-INH, both doses of berotralstat and both doses of lanadelumab, the risk in comparator group corresponds to the data in placebo arm of the corresponding study. For placebo, the risk in comparator group is estimated as the weighted average over the available data.

ARR: Absolute risk reduction; BIW: Twice weekly; C1-INH: C1-inhibitor; HAE: Hereditary angioedema; NMA: Network meta-analysis; Q2W: Every 2 weeks; Q4W: Every 4 weeks; q.d.: Once daily.